SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. reported a Q1 2026 net loss of $21.3 million, widening from $5.4 million a year earlier, mainly due to an $8.0 million in-process R&D charge for acquiring SCY-770 and higher operating costs. Research and development expense rose to $12.4 million, while selling, general and administrative expense increased to $4.6 million, including $0.8 million of financing-related costs. A warrant fair value loss of $5.2 million also weighed on results. Cash, cash equivalents and investments were $72.4 million as of March 31, 2026, supported by a March 2026 private placement with gross proceeds of $40.0 million. The company believes these resources fund operations for at least 12 months and is advancing SCY‑770 for autosomal dominant polycystic kidney disease and SCY‑247 for invasive fungal infections.
SCYNEXIS, Inc. filed a prospectus for the resale of up to 87,000,000 shares of Common Stock by the selling stockholders. The 87,000,000 shares comprise 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares.
The company will not receive proceeds from these resales, except for cash exercises of the Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. The shares were issued in a March 30, 2026 private placement at purchase prices of $0.92 per share with accompanying warrants and $0.9199 per Pre-Funded Warrant with accompanying warrants. The registration was filed to satisfy registration rights in the Purchase Agreement and related Registration Rights Agreement.
SCYNEXIS, Inc. registered up to 87,000,000 shares of Common Stock for resale by the purchasers in its March-April 2026 private placement (the "Selling Stockholders"). The registration covers 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares issuable upon exercise.
The company will not receive proceeds from resales, except for any cash exercises of Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. Shares outstanding were 79,442,633 as of April 1, 2026. The Common Stock last traded at $0.93 on April 30, 2026.
SCYNEXIS, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Proposals include electing six directors, ratifying Deloitte & Touche LLP, an advisory say-on-pay vote and say-on-pay frequency, and governance items.
The company seeks approval to amend its 2024 Equity Incentive Plan to increase the share reserve by 9,600,000 shares and to amend its certificate of incorporation to raise authorized common stock to either 60,000,000 or 300,000,000 shares, depending on a separate reverse stock split outcome. SCYNEXIS had 79,442,633 shares of common stock outstanding and entitled to vote as of April 27, 2026.
SCYNEXIS, Inc. Schedule 13G shows CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 3,008,874 shares of SCYNEXIS common stock, representing 6.7% of the class. The reported shares consist of warrants exercisable subject to 4.99% and 9.99% ownership caps. Shares outstanding were 41,924,941 as of August 8, 2025.
SCYNEXIS, Inc. is calling a virtual special stockholder meeting on May 19, 2026 to seek approval for a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑10, along with a proportional reduction in authorized shares. The board states this flexibility is intended to help the company regain compliance with The Nasdaq Capital Market’s minimum bid price requirement before June 15, 2026 and avoid potential delisting proceedings. As of April 20, 2026, the company had 79,442,633 common shares outstanding and 150,000,000 authorized, which would all be reduced proportionately if the split is implemented.
SCYNEXIS, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held on June 25, 2026. The Board asks shareholders to elect six directors, ratify Deloitte & Touche LLP as auditor, approve advisory votes on executive compensation and frequency, approve an increase to the 2024 Equity Incentive Plan share reserve, and approve an amendment to increase authorized common stock to either 60,000,000 (with a reverse split condition) or 300,000,000.
The record date was April 27, 2026. The Board recommends voting FOR all proposals, including a proposed 9,600,000-share increase to the 2024 Plan reserve and the plan amendment that results in a 21,410,683 share maximum under the amended plan. Proxy materials and voting instructions are available online.
SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.
Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.